January 27, 2023 08:30 AM ESTUpdated February 7, 09:29 AM

#JPM23: BeiGene CEO John Oyler on the com­pa­ny's big am­bi­tions

Drew Armstrong

Executive Editor

BeiGene CEO John Oyler and End­points News Ex­ec­u­tive Ed­i­tor Drew Arm­strong spoke one-on-one about where the drug­mak­er is head­ed in its quest to be­come a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times